Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33)

This grant provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. 

Funding: $750,000 total 

Duration: 3 years

Research Authority due dates: 10 days prior to submission

LOI (encouraged) due dates:  17.5.21, 19.9.21, 22.1.22, 21.5.22, 18.9.22, 21.1.23, 20.5.23, 20.9.23, 20.1.24

Full proposal due dates: 17.6.21, 19.10.21, 22.2.22, 21.6.22, 18.10.22, 21.2.23, 20.6.23, 20.10.23, 20.2.24